Kezar Life Sciences Reports Third Quarter 2023 Financial Res

13.11.2023 - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and ...

Related Keywords

San Diego , California , United States , China , Thailand , South Korea , Christopher Kirk , John Fowler , Rohit Aggarwal , Society For Immunotherapy Of Cancer , Kezar Life Sciences Stock , Asia Pacific League , Facebook , University Of Pittsburgh , Instagram , Nasdaq , American College Of Rheumatology , Exchange Commission , Linkedin , Kezar Life Sciences , Clinical Development , Twitter , Chief Executive Officer , Chief Scientific , Selective Immunoproteasome , Everest Medicines , Greater China , Label Extension , American College , Broad Spectrum Sec , Annual Meeting , David Bade , Senior Scientist , Life Sciences , Private Securities Litigation Reform Act , Kezar Life Sciences Chart , Ezar Life Sciences Kurs , Ezar Life Sciences Aktie ,